GWMIA
RIGL icon

Global Wealth Management Investment Advisory’s Rigel Pharmaceuticals RIGL Stock Holding History

Global Wealth Management Investment Advisory’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-16
Closed – – 747
2018
Q4 		$0 Buy
+16
New +$452 ﹤0.01% 718

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Global Wealth Management Investment Advisory's RIGL Position: Q1 2019 in Review

Global Wealth Management Investment Advisory sold out of Rigel Pharmaceuticals (RIGL) in Q1 2019, closing a stake of 16 shares.

Global Wealth Management Investment Advisory first reported a position in RIGL in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 131 funds tracked by Wall St. Rank hold RIGL as of Q1 2019.

  • Global Wealth Management Investment Advisory reported no remaining Rigel Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Global Wealth Management Investment Advisory sold 16 Rigel Pharmaceuticals shares in Q1 2019.
  • Global Wealth Management Investment Advisory first reported a position in Rigel Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Global Wealth Management Investment Advisory's Rigel Pharmaceuticals position peaked at $0 in Q4 2018.
  • 131 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2019.

Based on Global Wealth Management Investment Advisory's 13F filing for Q1 2019, filed 10 May 2019.